

In 2019, we made the following progress against the AMR Industry Alliance commitments:


Commitment

Update



Review our manufacturing and supply chains to assess good practices in managing the release of antibiotic discharge into the environment.

Pfizer completed environmental risk assessment of antibiotic discharges at internal manufacturing sites and has nearly completed those assessments in the rest of the world. The assessments conducted indicate good practices are being followed at many sites. Where warranted, action plans are being developed and implemented to mitigate risk.



Establish a common framework for managing antibiotic discharge building on exciting work such as the Pharmaceutical Supply Chain Initiative (PSCI) and apply these principles across our own internal manufacturing and external supply chain by 2018.

Pfizer has fully adopted the AMR Industry Alliance “[Common Antibiotic Manufacturing Framework](#),” and has verified through audit that the majority of our internal antibiotic manufacturing sites meet the framework. In addition, the expectations of the framework have been conveyed to all antibiotic suppliers, and assessments have been conducted against the framework for the majority of these suppliers.



Work with stakeholders to develop a practical mechanism to transparently demonstrate that our supply chains meet the standards in the framework.

[In 2019 Pfizer worked with the Alliance Manufacturing Group to agree on metrics/KPIs and gather performance data to include within an industry status report anticipated to publish in early 2020.](#)



Work with independent technical experts to establish science-driven, risk-based targets for discharge concentrations for antibiotics and good practice methods to reduce environmental impact of manufacturing discharges by 2020.

Pfizer continues to actively contribute as a founding member of the Alliance Manufacturing Group. In 2019 the Alliance established processes to evaluate new data and update as necessary the list of published risk-based discharge targets for a range of antibiotic compounds.